Feng-cai P. Zhu
87 Hunan Rd
Nanjing, 210009, China
Nanjing, 210009, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications
Adverse reaction characteristics of five COVID-19 vaccines across different technology platforms: a pooled analysis of nine clinical trials.
Journal: Expert review of vaccines
Published: May 07, 2025
COVID-19 immunisation strategies for adolescents.
Journal: The Lancet. Infectious diseases
Published: August 15, 2024
The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children.
Journal: The Lancet. Infectious diseases
Published: February 26, 2024
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.
Journal: The Lancet. Infectious diseases
Published: December 03, 2023
A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov.
Journal: Expert review of vaccines
Published: July 28, 2023
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.
Journal: Expert review of vaccines
Published: July 11, 2023
Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19.
Journal: Human vaccines & immunotherapeutics
Published: July 10, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Journal: The Lancet regional health. Western Pacific
Published: April 12, 2023
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
Journal: The Lancet. Infectious diseases
Published: April 04, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Journal: The Lancet. Infectious diseases
Published: March 14, 2023
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Journal: The Lancet. Infectious diseases
Published: February 20, 2023
Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
Journal: The Lancet regional health. Western Pacific
Published: February 06, 2023
Last Updated: 09/26/2026